Cobimetinib

Generic Name
Cobimetinib
Brand Names
Cotellic
Drug Type
Small Molecule
Chemical Formula
C21H21F3IN3O2
CAS Number
934660-93-2
Unique Ingredient Identifier
ER29L26N1X
Background

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...

Indication

Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.

Associated Conditions
Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

First Posted Date
2017-08-28
Last Posted Date
2021-05-11
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
87
Registration Number
NCT03264066
Locations
🇧🇪

AZ Groeninge, Kortrijk, Belgium

🇭🇺

Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 16 locations

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

First Posted Date
2017-07-21
Last Posted Date
2024-05-23
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
24
Registration Number
NCT03224767
Locations
🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

Sutter Roseville Medical Center, Roseville, California, United States

🇺🇸

Eden Hospital Medical Center, Castro Valley, California, United States

and more 103 locations

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

First Posted Date
2017-07-21
Last Posted Date
2021-04-26
Lead Sponsor
Fondazione Melanoma Onlus
Target Recruit Count
9
Registration Number
NCT03224208
Locations
🇮🇹

Fondazione G.Pascale, Napoli, Italy

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Alectinib
Drug: Cobimetinib
First Posted Date
2017-06-29
Last Posted Date
2024-04-23
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
16
Registration Number
NCT03202940
Locations
🇺🇸

Massachusetts general Hospital, Boston, Massachusetts, United States

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

First Posted Date
2017-06-28
Last Posted Date
2024-04-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
86
Registration Number
NCT03201458
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 38 locations

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

First Posted Date
2017-06-28
Last Posted Date
2024-10-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT03202316
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

First Posted Date
2017-06-20
Last Posted Date
2024-11-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
340
Registration Number
NCT03193190
Locations
🇺🇸

Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 24 locations

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

First Posted Date
2017-06-08
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT03181100
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2017-06-07
Last Posted Date
2024-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03178552
Locations
🇺🇸

UC Davis; Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Rocky Mountain Cancer Center, Denver, Colorado, United States

🇺🇸

SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States

and more 174 locations

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

First Posted Date
2017-06-07
Last Posted Date
2021-11-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
155
Registration Number
NCT03178851
Locations
🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

🇿🇦

Cancercare, Port Elizabeth, South Africa

🇦🇺

Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

and more 39 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy